Physiopathological Treatment Approach and Position of Pioglitazone in Type 2 Diabetes

Yıl 2017, , 220 - 223, 25.09.2017

Abdulhalim Şenyiğit , Mustafa Kanat

https://doi.org/10.21673/anadoluklin.284462

Cited By: 1

Öz

The glisemic controls are inadequate for over %50 of diabetic patients, despite modern treatment approaches in diabetes. Factors related with patient, physician and health system and also progressive character of the illness can be discussed in the issue that glisemic controls cannot be achieved adequately. The main principles of type 2 diabetes treatment and the position of pioglitazone as an insulin sensitizer were investigated in this revision.

Anahtar Kelimeler

Type 2 diabetes (T2DM), pioglitazone

Tip 2 Diyabette Fizyopatolojik Tedavi Yaklaşımı ve Pioglitazonun Yeri

Öz

Modern
diyabet tedavi yaklaşımlarına rağmen diyabetik hastaların %50’den fazlasında
glisemik kontroller yetersizdir. Glisemik kontrollerinin yeterince
gerçekleştirilememesinde hasta, hekim ve sağlık sistemini ilgilendiren
faktörler söz konusu olmakla beraber hastalığın progresif  bir karakterde olmasının da önemli etkisi söz
konusudur. Bu derlemede tip 2 diyabet tedavisinin ana ilkeleri ve insulin duyarlılaştırıcı
olarak pioglitazonun yeri gözden geçirilmiştir

Anahtar Kelimeler

Diyabet mellitus, Pioglitazon, İnsülin Direnci

Kaynakça

• 1. Defronzo RA: Banting Lecture. From the Triumvirate to the Ominous Octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 2009;58:773–795.
• 2. Defronzo RA, et al. Pathophysiologic Approach to Therapy in Patients with Newly Diagnosed Type 2 Diabetes. Diabetes Care 2013; 26 (Supplement 2): S127-S138.
• 3. DeFronzo RA: Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009. Diabetologia 2010;53:1270–1287.
• 4. Yki-Järvinen H. Thiazolidinediones. N Engl J Med 2004;351:1106–1118.
• 5. Eldor R. et al. In Vivo Actions of Peroxisome Proliferator-Activated Receptors. Diabetes Care 2013; 26 (Supplement 2): S162-S174.
• 6. Mazzone T, Meyer PM, Feinstein SB, et al. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. JAMA 2006;296:2572–2581 105.
• 7. Nissen SE, Nicholls SJ, Wolski K, et al.; PERISCOPE Investigators. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA 2008;299:1561– 1573 106.
• 8. Dormandy JA, Charbonnel B, Eckland DJ, et al.; PROactive investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005;366:1279–1289.
• 9. Kernan W.N. et al. Pioglitazone after Ischemic Stroke or Transient Ischemic Attack. N Engl J Med. 2016; 374: 1321-1331.
• 10. G. et al. Do We Still Need Pioglitazone for the Treatment of Type 2 Diabetes. Diabetes Care 2013; 26 (Supplement 2): S155-S161.
• 11. Standard of Medical Care in Diabetes 2017. Diabetes Care 2017; 40 (supplement 1): 64-74.